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ABSTRACT
Introduction Percutaneous coronary intervention (PCI) 
aims to provide instant relief of symptoms, and improve 
functional capacity and prognosis in patients with coronary 
artery disease. Although patients may experience a quick 
recovery, continuity of care from hospital to home can 
be challenging. Within a short time span, patients must 
adjust their lifestyle, incorporate medications and acquire 
new support. Thus, CONCARDPCI will identify bottlenecks 
in the patient journey from a patient perspective to 
lay the groundwork for integrated, coherent pathways 
with innovative modes of healthcare delivery. The main 
objective of the CONCARDPCI is to investigate (1) continuity 
of care, (2) health literacy and self- management, (3) 
adherence to treatment, and (4) healthcare utilisation and 
costs, and to determine associations with future short and 
long- term health outcomes in patients after PCI.
Methods and analysis This prospective multicentre 
cohort study organised in four thematic projects plans 
to include 3000 patients. All patients undergoing PCI at 
seven large PCI centres based in two Nordic countries 
are prospectively screened for eligibility and included in 
a cohort with a 1- year follow- up period including data 
collection of patient- reported outcomes (PRO) and a 
further 10- year follow- up for adverse events. In addition to 
PROs, data are collected from patient medical records and 
national compulsory registries.
Ethics and dissemination Approval has been granted 
by the Norwegian Regional Committee for Ethics in 
Medical Research in Western Norway (REK 2015/57), and 
the Data Protection Agency in the Zealand region (REG-
145-2017). Findings will be disseminated widely through 
peer- reviewed publications and to patients through patient 
organisations.
Trial registration number NCT03810612.
InTRoduCTIon
The widespread commitment to involve 
patients in planning and service develop-
ment has become a key element of current 
healthcare policy. Health literacy, as the 
ability to access, process and comprehend 
health information and services, can be used 
to complement both individual patient care 
and community- level development. Under-
standing the varying health literacy of patients, 
particularly in those who experience poor 
access and outcomes, is thereby pivotal.1 The 
American Heart Association (AHA) recently 
published a scientific statement2 addressing 
health literacy in cardiovascular disease as 
of fundamental relevance to primary and 
secondary prevention. European leaders in 
secondary prevention have called for action 
Strengths and limitations of this study
 ► The CONCARDPCI is an interdisciplinary, multicentre 
effort with the unique combination of data from 
hospital medical records, patient self- report and 
national registries providing opportunities to identify 
novel pathways for continuity of care that contribute 
to outcomes.
 ► Although the linkage to national registers will ensure 
complete follow- up of the study population, poten-
tial challenges include response rate of patient self- 
report at follow- up.
 ► Non- participants will be compared with participants 
on a limited number of registry variables to account 
for potential selection bias.
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Figure 1 Projects in CONCARDPCI researching bottlenecks 
for good and efficient patient pathways across levels of 
healthcare.
in the postacute aftercare of patients with coronary artery 
disease (CAD).3 Although CAD is the single most common 
cause of death in Europe, there has been an encouraging 
decrease in mortality ascribed to improvements in risk 
factor management, pharmacological treatment and 
revascularisation techniques.4 Since more people need 
to manage life with CAD as a chronic disease, modern 
developments in primary healthcare provision have led 
to increased interest in continuity of care as an essential 
element.5–7 Patients’ transition from hospital to home is 
particularly challenging because patients need to adjust 
their lifestyle, incorporate new medications and acquire 
additional sources of support.8 Although there is compel-
ling evidence for secondary prevention following CAD, a 
large majority fail to achieve lifestyle changes and thera-
peutic targets set by the European Society of Cardiology 
guidelines.9 Therefore, adherence to treatment is also of 
concern. Non- adherence to medications is common for 
patients with cardiovascular diseases.10 Taking prescribed 
antiplatelet and other secondary preventive medication 
after percutaneous coronary intervention (PCI) is pivotal; 
however, it is unknown if non- adherence also applies for 
patients following PCI.
This paper describes a multicentre cohort study, the 
CONCARDPCI, that seeks to identify bottlenecks and 
hurdles in the patient journey and suggest the optimal 
timing of services and alignment with patient preferences 
for patients with CAD undergoing PCI. Of special interest 
are challenges with continuity of care, health literacy and 
self- management, adherence to treatment advice, costs at 
all care levels and associations with future short and long- 
term health outcomes.
Uptake to cardiac rehabilitation (CR) is subop-
timal,9 11 12 and few sufficiently powered real- world studies 
have been undertaken with the explicit purpose of inves-
tigating continuity of care and pathways of CR in patients 
after PCI. In addition to investigating factors associated 
with low referral, participation, health literacy and adher-
ence rates among CR participants, studies are increasingly 
needed on evaluating alternative modes of providing CR. 
Follow- up of healthcare use, costs and predictors of costs 
following PCI in a non- clinical trial setting have been 
infrequently investigated.13 14 Thus, a large cohort of 
real- world observations that can ascertain interventions 
for future clinical trials is needed.15 The CONCARDPCI 
responds to this challenge. In CONCARDPCI, we hypoth-
esise that continuity of care, Health literacy and self- 
management, and adherence to treatment in patients are 
directly associated to outcomes after PCI.
AIM of ThE RESEARCh pRogRAMME
The overall aim of CONCARDPCI is to investigate (1) conti-
nuity of care, (2) health literacy and self- management, 
(3) adherence to treatment, and (4) healthcare utilisa-
tion and costs, to determine associations with future short 
and long- term health outcomes in patients after PCI. 
CONCARDPCI is organised into four thematic projects on 
continuity of care; health literacy and self- management; 
adherence to treatment; and healthcare use and costs 
(figure 1).
METhodS
Study design and setting
CONCARDPCI is a large- scale multicentre cohort study 
with serial prospective survey data collection, clinical 
data and register- based follow- up. We collect data from 
hospital medical records, patient self- report surveys and 
national registries (figure 2). Preliminary work has been 
performed including in- depth interviews on patients’ 
experiences of healthcare delivery to provide a context 
for the quantitative data and inform the content of the 
cohort survey questionnaires. Three follow- up surveys 
over 1 year are undertaken, and a 10- year follow- up for 
adverse events.
Seven large referral PCI centres in Norway and Denmark 
were selected based on the following considerations: pres-
ence of a committed research team including CONCAR-
DPCI study nurses and a local principal investigator, prior 
research experience including research infrastructure, 
geographical location and size. The PCI centres perform 
from 900 to >2000 (mean 1668) PCI procedures annually, 
are having 629–1400 beds (mean 943) and are referral 
centres for coronary angiography and PCI for a total of 37 
local hospitals (figure 3, table 1). Haukeland University 
Hospital is the sponsor centre of this investigator- initiated 
research programme. For study organisation, see online 
supplementary appendix.
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Figure 2 Measuring time points and data collection in the cohort study in CONCARDPCI.
Study population
All patients undergoing PCI at seven large PCI centres 
are prospectively screened for eligibility. Screening is 
performed in the hospital setting by the site coordinator 
and trained CONCARDPCI study nurses. Daily admission 
records and the operating programme are reviewed to 
identify potentially eligible patients. Electronic medical 
records are reviewed to confirm eligibility according to the 
inclusion and exclusion criteria (table 2). When cognitive 
impairment is suspected by clinical or study personnel and 
there is no medical record of the problem, the Confusion 
Assessment Method16 and 4AT17 are used to investigate 
whether the patient must be excluded. Patients who are 
delirious or too clinically unstable to participate following 
PCI, who would otherwise be eligible, are reassessed until 
discharge. During the in- hospital assessment, participants 
provide informed consent. Because many of the question-
naires are designed for patient self- assessment, patients 
who need a complete proxy are ineligible. If participants 
need assistance in filling out the questionnaires, this is 
registered in the case report form (CRF). Regarding 
sample size and study power, see the Data analysis and 
sample size determination section.
Measurement and data collection
In CONCARDPCI a broad range of outcomes are measured 
and data are collected by physical assessment at baseline, 
review of the medical records, patient self- reported ques-
tionnaires (at baseline, 2, 6 and 12 months) and from 
national registries (table 3 and figure 2). A comprehen-
sive data dictionary and CRF are provided to ensure stan-
dardisation of abstracted data. For the Danish centres, 
eCRFs are used. Patients included in the study undergo 
a brief physical assessment and complete the self- report 
questionnaires at baseline after PCI (T0) (table 3 and 
figure 2). A follow- up with postal or electronic ques-
tionnaires is distributed to all patients included in the 
study, 2 months after discharge (T1). The time interval 
ensures time for follow- up care to evaluate early post-
discharge continuity of care. A consecutive subgroup of 
patients (n=100) at the Sponsor Coordinating Centre 
are approached for a retest of the eHealth Literacy Scale 
(eHEALS)18 and the Heart Continuity of Care Question-
naire (HCCQ)19 as part of the validation process of the 
instruments. All patients are followed up with postal or 
electronic questionnaires at 2 (T1), 6 (T2) and 12 (T3) 
months after discharge. Non- responders receive one 
reminder. Vital status is identified to avoid sending ques-
tionnaires to deceased patients or their family. Patient 
adverse events are followed through national registers 
for 10 years or until death (T4) (figure 2). Questionnaire 
packages are discussed with patient representatives and 
piloted at every measuring time point (T0–T3) before 
employed in the large- scale cohort study.
To objectively assess adherence to therapy, serum levels 
of a wide panel of cardiac medications are measured. A 
consecutive subsample of 500 Norwegian patients from 
two centres will be invited to give a blood sample 1 year 
after the index procedure. The time is chosen as it corre-
sponds to collection of patient- reported data on adher-
ence. Moreover, adherence tends to diminish over time20; 
hence, the 1- year contact was chosen. Serum levels are 
submitted to an accredited clinical pharmacology labo-
ratory, and quantified using liquid chromatography with 
mass spectrometry. Patients are labelled as non- adherent 
when serum level of at least one of the evaluated drugs is 
below the limit of quantification.
Management of cohort and registry data
For the Norwegian centres, baseline (T0) data are trans-
ferred to the National Coordinating Centre for data 
entry and/or review. The forms are reviewed and queries 
sent to the centre for missing or incomplete items. All 
follow- up data are collected by postal mail and managed 
at the National Coordinating Centre. The paper version 
data are entered into electronic files by trained staff.
For the Danish centres, each centre registers patients who 
are screened, and either included or excluded in sepa-
rate Microsoft Excel (V.2016) spreadsheets in a shared 
secure team site server hosted by the National Coordi-
nating Centre. Data from medical records are entered 
into a shared SurveyXact (V.12.9) database at each study 
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Figure 3 H=PCI centres including the local hospitals in their catchment area.
site and managed by the National Coordinating Centre. 
Patient self- reports at both baseline (T0) and follow- up 
are collected either electronically using a tablet via a 
SurveyXact link or by paper as requested by the patient. 
Paper version data are entered into the SurveyXact data-
base by trained CONCARDPCI study nurses. All follow- up 
data are collected and managed by the National Coordi-
nating Centre.
Every resident in Norway and Denmark has a unique 
personal identifier that allows data sets from national 
registries to be merged on an individual level. The data 
sets will be released in a coded and deidentified form, 
but with a unique identifier common to the data sets 
making individual merging possible. The heart registries, 
prescription registries,21 22 cause of death registries23 24 
and administrative registries on social security microdata 
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Table 1 Description of centres participating in CONCARDPCI
Centre 1
(HUS)
Centre 2
(SUS)
Centre 3
(RHOsl)
Centre 4
(HGH)
Centre 5
(ZUH)
Centre 6
(RHCph)*
Centre 7
(OUH)
Total hospital beds 1400 482 697 949 629 1377 1064
PCI procedures per year† 1565 905 2124 1290 921 2243 2633
Catchment area of number of local hospitals 7 1 9 4 5 5 6
Centre 1 is the Sponsor Coordinating Centre.
*RHCph has regional function for all patients with ST- elevation myocardial infarction affiliated to the capital region and Zealand region.
†Figures from 2017.
HGH, Herlev and Gentofte University Hospital, Copenhagen, Denmark; HUS, Haukeland University Hospital, Bergen, Norway; OUH, Odense 
University Hospital, Odense, Denmark; PCI, percutaneous coronary intervention; RHCph, Copenhagen University Hospital, Rigshospitalet, 
Copenhagen, Denmark; RHOsl, Oslo University Hospital, Rikshospitalet, Oslo, Norway; SUS, Stavanger University Hospital, Stavanger, 
Norway; ZUH, Zealand University Hospital, Roskilde, Denmark.
Table 2 Eligibility criteria for CONCARDPCI
Inclusion 
criteria
 ► Patients undergoing percutaneous coronary 
intervention (PCI)
 ► ≥18 years of age
 ► Living at home at the time of index 
hospitalisation and inclusion
 ► Informed consent
Exclusion 
criteria
 ► Patients who do not speak Norwegian/
Danish
 ► Patients who are unable to fill in the 
questionnaires due to reduced capacities
 ► Patients who are institutionalised
 ► Patients with expected lifetime less than 1 
year
 ► Patients undergoing PCI without stent 
implementation, or related to transcatheter 
aortic valve implantation (TAVI) or MitraClip 
examination
 ► Previous enrolment in CONCARDPCI 
(readmissions)
and healthcare utilisation25 26 are mandatory, and legally 
exempted from requirement of obtaining patient 
consent. Strict rules on how data can be used or linked 
are followed to secure privacy protection. Although 
these data are similar in composition, we are interested 
in contrasting and comparing Denmark with its high CR 
uptake to Norway with a lower uptake.
data analysis and sample size determination
Descriptive statistics of the cohort by nation will be gener-
ated using proportions, means and SDs or medians and 
IQRs as appropriate. Cross- sectional analysis will be used 
for continuity of care (table 4) using multiple linear 
regression testing for a random effect for nation. For 
health literacy, there is a single follow- up and multiple 
linear regression testing for a random nation effect will be 
used. The cohort’s longitudinal observations over 1 year 
will be modelled using generalised linear mixed models 
(GLMM) that account for within- person correlation for 
adherence to medications, healthcare utilisation and cost 
(table 4). We will test whether patients clustered within 
nation is significant. If so, we will include it as a hierarchy 
in the GLMMs. For time to readmission, and time to major 
adverse cardiac event, we will use competing risk models 
to account for censoring by death. We will construct risk 
stratification models that predict the probability of each 
outcome for specific combinations of risk factors. We will 
establish internal validity by using bootstrapping tech-
niques. We will test whether missing data are at random. 
If not, we will estimate the probability of missingness and 
include it as a weight or covariate factor in the models. 
For psychometric evaluation of translated instruments 
we evaluate the structural, discriminant and convergent 
validity, and reliability of the scales. For internal consis-
tency, Cronbach’s alpha is used. Test–retest reliability 
is evaluated by using intraclass correlation coefficients 
of patients’ results obtained at a 2- week retest interval. 
Confirmatory factor analysis is used for evaluating the 
factor structure of the original eHEALS18 and HCCQ19 
instruments.
Power calculations for the cohort study are based on 
time- to- first event outcomes, as these require the most 
patients. To maintain at family- wise type I error of 0.05% 
and 80% power using the method of Hsieh and Lavori27 
for adjusted Cox regression models 2550 patients are 
needed. To adjust for losses to follow- up, we increased 
this estimate by 18% for a total of 3000 patients. Thus, all 
outcomes will have ≥80% power with alpha ≤0.05.
EThICS AppRovAl And ConSEnT To pARTICIpATE
The ethical guidelines of the World Medical Association, 
Declaration of Helsinki and the legislation in Norway and 
Denmark guide the study (Declaration of Helsinki, 2008). 
At inclusion, a detailed letter informing the potential 
participant of the study, and the right to withdraw from the 
study at any time without any reason is underlined. The 
identifying key is kept in a separate file from the data. The 
data are kept in strict confidence in locked files at research 
servers to protect the participants’ privacy. Approval by 
the Norwegian Regional Committee for Ethics in Medical 
Research in Western Norway has been granted (REK 
2015/57), and from the Data Protection Agency in the 
Zealand region for the Danish centres (REG-145-2017). 
Written agreements between the Sponsor Coordinating 
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Centre, and the local principal investigators and directors 
of the departments in each participating study centre, are 
signed before initiation of data collection. The study is 
registered at  ClinicalTrials. gov.
pATIEnT And uSER InvolvEMEnT
CONCARDPCI involves patients and stakeholders to 
target aspects of the patient journey to identify bottle-
necks and carve out a user- friendly intervention. Patient 
involvement is carried out in several ways: two patient 
representatives with a history of CAD, and trained to be 
patient representatives both in healthcare and research 
settings,28 provide input to the planning, implementing 
and reporting of results from the study. Representatives 
from all healthcare levels will be end users of knowledge 
from the project and are actively involved in the project 
through the CONCARDPCI Expert Group (online supple-
mentary appendix). Reporting of patient involvement 
will follow the GRIPP2 reporting checklists.29
CoMMunICATIon of RESulTS And TRAnSITIon of 
knowlEdgE
The CONCARDPCI has a close- to- practice and clinical 
approach, which will be an advantage in dissemina-
tion and communication with end users. Results will be 
disseminated to patients through patient organisations, 
and to healthcare professionals in PCI treatment teams 
and CR teams, as well as in primary care through semi-
nars and scientific meetings. Due to the comprehensive-
ness of the outcome measures in the thematic projects 
(table 4), numerous scientific papers are expected. Long- 
term follow- up will be reported as data become acces-
sible. Authorship on publications from the study will be 
allocated using the guidelines for authorship defined by 
the International Committee of Medical Journal Editors 
and depends on personal involvement.
dISCuSSIon
While medicine has produced large advances in cardiac 
treatment, there is need for more consistent patient path-
ways and systematic follow- up care. In order to do so, 
bottlenecks in the patient journey need to be identified. 
CONCARDPCI aims to close knowledge gaps related to 
four main areas: (1) continuity of care, (2) health literacy 
and self- management, (3) adherence to treatment, and 
(4) healthcare utilisation and costs of care. Although 
landmark cohort studies have been carried out to describe 
the aftercare of patients after acute myocardial infarction 
(MI), less is described of the patient journey, specifically 
after PCI, and rarely have these included extensive self- 
report from patients. In the past decade, an increasing 
number of studies using patient- reported outcomes have 
been performed, but in a different setting, with shorter 
follow- up and targeting subgroups of patients with 
acute MI.30–34 The US- based SILVER- AMI study focused 
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Table 4 Definition of outcomes in CONCARDPCI
Outcome Definition
Continuity of care As measured by the Heart Continuity of Care Questionnaire (HCCQ).19
Health literacy and eHealth 
literacy
As measured by the Health Literacy Questionnaire (HLQ)44 and eHealth Literacy Scale (eHEALS) 
questionnaire.18
Adherence to medication As measured by the Medication Adherence Report Scale (MARS-5),46 Beliefs about Medicines 
Questionnaire (BMQ)42 and data related to consumption of prescribed medication identified through 
national prescription registries, and serum levels of cardiac medication.
Healthcare utilisation As measured by patients’ use of primary care services (general practitioner visits) and secondary care 
services (inpatient admissions and outpatient visits).
Healthcare (associated) costs As measured by the tariffs of national agreements between the professional associations of medical 
specialists and the National Health Services, and the tariffs of the national case- mix system of the 
diagnosis- related groupings (DRG) and the Danish Ambulatory Grouping System (DAGS).
Time to readmission Cardiac and all- cause readmissions.
Time to death Cardiac and all- cause mortality.
Time to major adverse cardiac 
events (MACE)
A composite of cardiac mortality and hospitalisation for cardiovascular disease or chest pain.
on older adults,30 the VIRGO study31 concentrated on 
younger women after acute MI, TRIUMPH32 was designed 
to examine racial differences after acute MI, Vanderbilt 
Inpatient Cohort Study33 included both patients after 
acute MI and patients with heart failure, and NOR- COR34 
retrospectively surveyed patients below 80 years of age 
2–38 months after the index event including also patients 
with coronary artery bypass surgery or no intervention. 
Age is of particular concern as it is documented that inva-
sive strategies benefit clinically stable very old patients 
with non- ST- elevation acute coronary syndrome.35 In 
contrast, CONCARDPCI has an extended perspective by 
prospectively including adult patients with no age limit, 
engaging stakeholders throughout the study, applying a 
comprehensive interdisciplinary approach and including 
data from national registries. One great asset of the partic-
ipating Nordic countries is infrastructure in research with 
access to demographics and health information through 
the national registries. The registries include all citizens, 
and a personal identifying number ensures no loss to 
follow- up. In addition to national compulsory registries 
on death (National Death Registry),23 24 readmission and 
use of healthcare services (National Patient Registry)25 26 
and prescription and medication consumption (National 
Prescription Registry),21 22 the countries have disease- 
specific national medical quality registries (eg, the Norwe-
gian Registry of Invasive Cardiology). With establishing 
national registries, opportunities for nationwide compar-
isons and quality improvement of healthcare service are 
created.
While the aforementioned studies30–34 also have 
detailed data abstracted from medical records and self- 
report, CONCARDPCI has a timely approach in the four 
thematic projects—one of which concerns health literacy, 
and specifically eHealth literacy is of particular relevance 
in information technology- driven societies. The AHA 
Scientific Statement on health literacy2 calls for studies 
examining health literacy and cardiovascular outcomes 
beyond 30- day readmission. It is suggested that health 
literacy can be evaluated as part of programmes aiming 
to improve secondary prevention in that health literacy 
influences dropout rates in CR. CONCARDPCI responds 
to this challenge.
Lack of continuity of care and low health literacy are 
likely to carry increased healthcare utilisation (eg, read-
mission to hospital) and increased cost.36 The potential 
need for rethinking CR based on patient preferences 
and in- built economic analysis is a relevant path to follow. 
Moving towards a more patient- centred care aims to 
maximise patients’ self- care abilities. Increased self- care 
is an overarching goal when healthcare expenditure rises 
to unaffordable levels. Further, in additional parame-
ters, patient- reported outcomes can potentially identify 
patients at high risk of adverse outcomes and hospital 
readmissions,37 38 which is of importance both to patients 
and society.
The importance of increased patient involvement 
and shared decision- making at all levels of healthcare is 
underlined in policy documents at a governmental and 
regional level.39 Patient involvement is a unique feature 
of CONCARDPCI scarcely described in comparable large- 
scale studies. The use of standardised patient- reported 
outcome measures may provide information that can 
assist in this decision- making.37 38 In CONCARDPCI, we 
include patient- reported outcome measures on a global, 
generic and disease- specific level,40 and pose research 
questions related to patient pathways that concern a large 
group of patients. We anticipate that treatment outcome 
(adherence), safe communication (continuity and health 
literacy) and self- management will prove important to 
future healthcare.
However, the study has some limitations. We lack partic-
ipating hospitals from northern Norway. The remoteness 
and distance to the PCI centre is a feature of that area 
and therefore of particular concern. However, travel time 
to the PCI centre from the most remote fjords in western 
9Norekvål TM, et al. BMJ Open 2020;10:e031995. doi:10.1136/bmjopen-2019-031995
Open access
Norway is also long and this catchment area is included 
in the study (figure 3). Further, we exclude patients with 
delirium and dementia due to ethical reasons regarding 
informed consent and logistical difficulties. Delirious 
patients and patients too clinically unstable to be included 
following the PCI procedure, who would otherwise be 
eligible, are reassessed until discharge. Non- participants 
will be compared with participants on a limited number 
of registry variables to account for potential selection 
bias. Extensive self- report is a feature of CONCARDPCI, 
and we use validated questionnaires and only a few de 
novo created questions based on patient interviews. Still, 
the response rate of follow- up (T1–T3) may be a poten-
tial limitation. However, previous methodological work in 
patients with CAD showed high acceptability of compre-
hensive questionnaires41 and patient representatives 
participating in planning of CONCARDPCI ensured rele-
vance of the questionnaires.
STATuS
Data collection for the cohort study commenced on 12 
June 2017 and is expected to continue until July 2020, 
with a 10- year follow- up until July 2029. The inclusion of 
patients for the blood sampling for objective medication 
adherence measurement has started.
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